• Helen H. Kim
  • Sabrina Holmquist


Unplanned and teen pregnancies have important public health consequences and may be particularly deleterious in women with endocrine disease. Given the risks of unplanned pregnancy, particularly in teens with endocrine disorders, it is imperative to address contraception with these patients. There are many forms of hormonal and nonhormonal contraception available, and each contraceptive method has its own set of advantages and limitations. Because hormonal methods are metabolically active, it is necessary to consider the possible interactions with the patient’s disease or medical treatment. The selection of a contraceptive method for patients with endocrine disorders may require additional considerations. There are also special considerations for the obese adolescent.

Generally, the adolescent population is low risk, and these additional considerations should not be a deterrent to the use of hormonal contraception. Hormonal contraceptive methods may be particularly well-suited for adolescents since contraindications, such as risk factors for cardiovascular disease, are rarely seen. In addition to providing reliable contraception, hormonal methods also provide many noncontraceptive health benefits, including protection from certain cancers. Hormonal contraceptive methods have been used in management of acne, hirsutism, and irregular menstrual cycles, which may be particularly relevant for adolescents with endocrine disorders. Long-acting methods, such as IUDs, have extremely low failure rates and fewer systemic side effects and may be particularly beneficial for adolescents with endocrine disorders.


Contraception IUD Oral contraceptive pills Combined hormonal contraception DMPA Etonogestrel implant Emergency contraception Contraception benefits 



The authors wish to thank Amy K. Whitaker, MD, for her contribution to this chapter in the previous edition.


  1. 1.
    Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med. 2016;374:843–52.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Ventura SJ, Hamilton BE, Matthews TJ. National and state patterns of teen births in the United States, 1940-2013. Natl Vital Stat Rep. 2014;63:1–34.PubMedGoogle Scholar
  3. 3.
    Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med. 1990;323:91–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Alexander EK, Pearce EN, Brent GA, et al. 2016 Guidelines of the American Thyroid Association for the diagnosis and Management of Thyroid Disease during pregnancy and the postpartum. Thyroid 2017.Google Scholar
  5. 5.
    Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341:549–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4227–49.PubMedCrossRefGoogle Scholar
  7. 7.
    ADA. (12) Management of diabetes in pregnancy. Diabetes care. 2015;38(Suppl):S77–9.Google Scholar
  8. 8.
    Lindberg L, Santelli J, Desai S. Understanding the decline in adolescent fertility in the United States, 2007-2012. J Adolesc Health. 2016;59:577–83.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Kost KAM-ZI. U.S. teenage pregnancies, births and abortions, 2011: state trends by age, race and ethnicity. New York: Guttmacher Institute; 2016.Google Scholar
  10. 10.
    Santelli J, Sandfort T, Orr M. Transnational comparisons of adolescent contraceptive use: what can we learn from these comparisons? Arch Pediatr Adolesc Med. 2008;162:92–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Sedgh G, Finer LB, Bankole A, Eilers MA, Singh S. Adolescent pregnancy, birth, and abortion rates across countries: levels and recent trends. J Adolesc Health. 2015;56:223–30.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Martinez GM, Abma JC. Sexual activity, contraceptive use, and childbearing of teenagers aged 15-19 in the United States. NCHS Data Brief. 2015;(209):1–8.Google Scholar
  13. 13.
    Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the 2002 National Survey of family growth. Contraception. 2008;77:10–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–103.PubMedGoogle Scholar
  15. 15.
    ACOG. ACOG practice bulletin no. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010;115:206–18.CrossRefGoogle Scholar
  16. 16.
    Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1–137.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Martinez G, Copen CE, Abma JC. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006–2010 national survey of family growth. Vital Health Stat 23, Data from the National Survey of Family Growth. 2011:1–35.Google Scholar
  19. 19.
    Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal DMP, eds. Contraceptive technology. 19th. New York (NY): Ardent Media; 2011.Google Scholar
  20. 20.
    Cates WJ. Sexually transmitted diseases, HIV, and contraception. Infertil Reprod Med Clin North Am. 2000;11:669–704.Google Scholar
  21. 21.
    Gimenes F, Souza RP, Bento JC, et al. Male infertility: a public health issue caused by sexually transmitted pathogens. Nat Rev Urol. 2014;11:672–87.PubMedCrossRefGoogle Scholar
  22. 22.
    McCormack WM. Pelvic inflammatory disease. N Engl J Med. 1994;330:115–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Westrom L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol. 1980;138:880–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive technology. 19th ed. New York (NY): Ardent Media; 2007.Google Scholar
  25. 25.
    Gilliam ML, Derman RJ. Barrier methods of contraception. Obstet Gynecol Clin N Am. 2000;27:841–58.CrossRefGoogle Scholar
  26. 26.
    Schwartz B, Gaventa S, Broome CV, et al. Nonmenstrual toxic shock syndrome associated with barrier contraceptives: report of a case-control study. Rev Infect Dis. 1989;11(Suppl 1):S43–8. discussion S8-9PubMedCrossRefGoogle Scholar
  27. 27.
    Fihn SD, Latham RH, Roberts P, Running K, Stamm WE. Association between diaphragm use and urinary tract infection. JAMA. 1985;254:240–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Hooton TM, Hillier S, Johnson C, Roberts PL, Stamm WE. Escherichia coli bacteriuria and contraceptive method. JAMA. 1991;265:64–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Kavanaugh ML, Jerman J, Finer LB. Changes in use of long-acting reversible contraceptive methods among U.S. Women, 2009-2012. Obstet Gynecol. 2015;126:917–27.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Daniels K, Daugherty J, Jones J, Mosher W. Current contraceptive use and variation by selected characteristics among women aged 15-44: United States, 2011-2013. Natl Health Stat Rep. 2015;10:1–14.Google Scholar
  31. 31.
    McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration. Obstet Gynecol. 2015;125:599–604.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339:785–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49:56–72.PubMedCrossRefGoogle Scholar
  34. 34.
    Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345:561–7.PubMedCrossRefGoogle Scholar
  35. 35.
    ACOG. ACOG Committee opinion no. 392, December 2007. Intrauterine device and adolescents. Obstet Gynecol. 2007;110:1493–5.CrossRefGoogle Scholar
  36. 36.
    Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. Contraception. 2009;79:418–23.PubMedCrossRefGoogle Scholar
  37. 37.
    Hannaford PC, Webb AM. Evidence-guided prescribing of combined oral contraceptives: consensus statement. An International Workshop at Mottram Hall, Wilmslow, U.K., March, 1996. Contraception. 1996;54:125–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Croxatto HB, Diaz S, Salvatierra AM, Morales P, Ebensperger C, Brandeis A. Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro. Contraception. 1987;36:193–201.PubMedCrossRefGoogle Scholar
  39. 39.
    Johannisson E, Landgren BM, Diczfalusy E. Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with the 300 microgram norethisterone (NET) minipill. Contraception. 1982;25:13–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Baird DT, Glasier AF. Hormonal contraception. N Engl J Med. 1993;328:1543–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Clark LR. Will the pill make me sterile? Addressing reproductive health concerns and strategies to improve adherence to hormonal contraceptive regimens in adolescent girls. J Pediatr Adolesc Gynecol. 2001;14:153–62.PubMedCrossRefGoogle Scholar
  42. 42.
    Raine TR, Foster-Rosales A, Upadhyay UD, et al. One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives. Obstet Gynecol. 2011;117:363–71.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577–82.PubMedCrossRefGoogle Scholar
  44. 44.
    Dickey RP. Managing contraceptive pill/drug patients. 14th ed. New Orleans: EMIS, Inc.; 2010.Google Scholar
  45. 45.
    Thorneycroft IH. New pills/new Progestins. Infertil Reprod Med Clin North Am. 2000;11:515–29.Google Scholar
  46. 46.
    Goldzieher JW. Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications. Am J Obstet Gynecol. 1990;163:318–22.PubMedCrossRefGoogle Scholar
  47. 47.
    Goldzieher JW, Brody SA. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol. 1990;163:2114–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Speroff L. Oral contraceptives and arterial and venous thrombosis: a clinician's formulation. Am J Obstet Gynecol. 1998;179:S25–36.PubMedCrossRefGoogle Scholar
  49. 49.
    Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62:29–38.PubMedCrossRefGoogle Scholar
  50. 50.
    Oelkers W. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care. 2000;5(Suppl 3):17–24.PubMedGoogle Scholar
  51. 51.
    Cremer M, Phan-Weston S, Jacobs A. Recent innovations in oral contraception. Semin Reprod Med. 2010;28:140–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–6.PubMedGoogle Scholar
  53. 53.
    Cachrimanidou AC, Hellberg D, Nilsson S, Waldenstrom U, Olsson SE, Sikstrom B. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception. 1993;48:205–16.PubMedCrossRefGoogle Scholar
  54. 54.
    Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol. 1997;89:179–83.PubMedCrossRefGoogle Scholar
  55. 55.
    van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168–74.PubMedCrossRefGoogle Scholar
  56. 56.
    ACOG. ACOG practice bulletin no. 108: polycystic ovary syndrome. Obstet Gynecol. 2009;114:936–49.CrossRefGoogle Scholar
  57. 57.
    McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception. 1994;50:S1–195.PubMedCrossRefGoogle Scholar
  58. 58.
    Speroff L, Darney P. A clinical guide for contraception. 4th ed. Baltimore: Williams and Wilkins; 2005.Google Scholar
  59. 59.
    Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23, Data from the National Survey of Family Growth. 2010:1–44.Google Scholar
  60. 60.
    Sneed R, Westhoff C, Morroni C, Tiezzi L. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception. 2005;71:99–103.PubMedCrossRefGoogle Scholar
  61. 61.
    Kaunitz AM. Injectable Contraception. Infertil Reprod Med Clin North Am. 2000;11:609–43.Google Scholar
  62. 62.
    Mishell DR Jr. Cardiovascular risks: perception versus reality. Contraception. 1999;59:21S–4S.PubMedCrossRefGoogle Scholar
  63. 63.
    Clark MK, Sowers M, Levy BT, Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril. 2001;75:871–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Harel Z, Biro FM, Kollar LM, Rauh JL. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant. J Adolesc Health. 1996;19:118–23.PubMedCrossRefGoogle Scholar
  65. 65.
    Sangi-Haghpeykar H, Poindexter AN 3rd, Bateman L, Ditmore JR. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol. 1996;88:227–33.PubMedCrossRefGoogle Scholar
  66. 66.
    Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception. 1995;51:149–53.PubMedCrossRefGoogle Scholar
  67. 67.
    Lei ZW, SC W, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception. 1996;53:357–61.PubMedCrossRefGoogle Scholar
  68. 68.
    Zibners A, Cromer BA, Hayes J. Comparison of continuation rates for hormonal contraception among adolescents. J Pediatr Adolesc Gynecol. 1999;12:90–4.PubMedCrossRefGoogle Scholar
  69. 69.
    Westhoff C, Truman C, Kalmuss D, et al. Depressive symptoms and Depo-Provera. Contraception. 1998;57:237–40.PubMedCrossRefGoogle Scholar
  70. 70.
    Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. BJOG. 2001;108:1214–21.PubMedGoogle Scholar
  71. 71.
    Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002;13:581–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86:1466–74.PubMedCrossRefGoogle Scholar
  73. 73.
    Depo-Provera Physician Information [Label]. Kalamazoo, MI: Pfizer; 2004.Google Scholar
  74. 74.
    Davies JH, Evans BA, Gregory JW. Bone mass acquisition in healthy children. Arch Dis Child. 2005;90:373–8.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Lloyd T, Rollings N, Andon MB, et al. Determinants of bone density in young women. I. Relationships among pubertal development, total body bone mass, and total body bone density in premenarchal females. J Clin Endocrinol Metab. 1992;75:383–7.PubMedGoogle Scholar
  76. 76.
    Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004;35:434–41.PubMedCrossRefGoogle Scholar
  77. 77.
    Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139–44.PubMedCrossRefGoogle Scholar
  78. 78.
    Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010;81:281–91.PubMedCrossRefGoogle Scholar
  79. 79.
    WHO. WHO statement on hormonal contraception and bone health. Wkly Epidemiol Rec. 2005;80:302–4.Google Scholar
  80. 80.
    ACOG. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453–72.CrossRefGoogle Scholar
  81. 81.
    Cromer B, Harel Z. Adolescents: at increased risk for osteoporosis? Clin Pediatr (Phila). 2000;39:565–74.CrossRefGoogle Scholar
  82. 82.
    Hohmann H, Creinin MD. The contraceptive implant. Clin Obstet Gynecol. 2007;50:907–17.PubMedCrossRefGoogle Scholar
  83. 83.
    Croxatto HB, Urbancsek J, Massai R, Coelingh Bennink H, van Beek AA. Multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod. 1999;14:976–81.PubMedCrossRefGoogle Scholar
  84. 84.
    Funk S, Miller MM, Mishell DR Jr, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005;71:319–26.PubMedCrossRefGoogle Scholar
  85. 85.
    Beerthuizen R, van Beek A, Massai R, Makarainen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod. 2000;15:118–22.PubMedCrossRefGoogle Scholar
  86. 86.
    Turok DK, Godfrey EM, Wojdyla D, Dermish A, Torres L, Copper WSC. T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle. Hum Reprod. 2013;28:2672–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. Natl Health Stat Rep. 2012:1–25.Google Scholar
  88. 88.
    Moreau C, Trussell J. Results from pooled Phase III studies of ulipristal acetate for emergency contraception. Contraception. 2012;86:673–80.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375:555–62.PubMedCrossRefGoogle Scholar
  90. 90.
    Ory HW. Cardiovascular safety of oral contraceptives. What has changed in the last decade? Contraception. 1998;58:9S–13S. quiz 65SPubMedCrossRefGoogle Scholar
  91. 91.
    Carr BR, Ory H. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception. 1997;55:267–72.PubMedCrossRefGoogle Scholar
  92. 92.
    Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323:1375–81.PubMedCrossRefGoogle Scholar
  93. 93.
    Wynn V, Godsland I. Effects of oral contraceptives on carbohydrate metabolism. J Reprod Med. 1986;31:892–7.PubMedGoogle Scholar
  94. 94.
    Fahmy K, Abdel-Razik M, Shaaraway M, et al. Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. Contraception. 1991;44:419–30.PubMedCrossRefGoogle Scholar
  95. 95.
    Liew DF, Ng CS, Yong YM, Ratnam SS. Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception. 1985;31:51–64.PubMedCrossRefGoogle Scholar
  96. 96.
    Berenson AB, van den Berg P, Williams KJ, Rahman M. Effect of injectable and oral contraceptives on glucose and insulin levels. Obstet Gynecol. 2011;117:41–7.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Biswas A, Viegas OA, Coeling Bennink HJ, Korver T, Ratnam SS. Implanon contraceptive implants: effects on carbohydrate metabolism. Contraception. 2001;63:137–41.PubMedCrossRefGoogle Scholar
  98. 98.
    Bowes WA Jr, Katta LR, Droegemueller W, Bright TG. Triphasic randomized clinical trial: comparison of effects on carbohydrate metabolism. Am J Obstet Gynecol. 1989;161:1402–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2014 Apr 30;(4):CD006133.Google Scholar
  100. 100.
    Gaspard UJ, Lefebvre PJ. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. Am J Obstet Gynecol. 1990;163:334–43.PubMedCrossRefGoogle Scholar
  101. 101.
    Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA. 1998;280:533–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Heroux K. Contraceptive choices in medically ill adolescents. Semin Reprod Med. 2003;21:389–98.PubMedCrossRefGoogle Scholar
  103. 103.
    Skouby SO. Hormonal contraception in obesity, the metabolic syndrome, and diabetes. Ann N Y Acad Sci. 2010;1205:240–4.PubMedCrossRefGoogle Scholar
  104. 104.
    Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA. 1994;271:1099–102.PubMedCrossRefGoogle Scholar
  105. 105.
    Klein BE, Moss SE, Klein R. Oral contraceptives in women with diabetes. Diabetes Care. 1990;13(8):895.PubMedCrossRefGoogle Scholar
  106. 106.
    Rogovskaya S, Rivera R, Grimes DA, et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol. 2005;105:811–5.PubMedCrossRefGoogle Scholar
  107. 107.
    Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res. 2000;26:17–26.PubMedCrossRefGoogle Scholar
  108. 108.
    Fruzzetti F, Ricci C, Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception. 1994;49:579–92.PubMedCrossRefGoogle Scholar
  109. 109.
    Westhoff CL. Oral contraceptives and thrombosis: an overview of study methods and recent results. Am J Obstet Gynecol. 1998;179:S38–42.PubMedCrossRefGoogle Scholar
  110. 110.
    ASRM. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017;107:43–51.CrossRefGoogle Scholar
  111. 111.
    Sitruk-Ware R. Hormonal contraception and thrombosis. Fertil Steril. 2016;106:1289–94.PubMedCrossRefGoogle Scholar
  112. 112.
    Speroff L. Oral contraceptives and arterial and venous thrombosis: a clinician's formulation. Am J Obstet Gynecol. 1998;179:S25–36.PubMedCrossRefGoogle Scholar
  113. 113.
    Spitzer WO. The 1995 pill scare revisited: anatomy of a non-epidemic. Hum Reprod. 1997;12:2347–57.PubMedCrossRefGoogle Scholar
  114. 114.
    Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997;277:1305–7.PubMedCrossRefGoogle Scholar
  115. 115.
    Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med. 2001;344:1743–9.PubMedCrossRefGoogle Scholar
  116. 116.
    Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–66.PubMedGoogle Scholar
  117. 117.
    Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16:631–50.PubMedCrossRefGoogle Scholar
  118. 118.
    CGHFBC. Breast cancer and hormonal contraceptives: further results. Collaborative group on hormonal factors in breast cancer. Contraception. 1996;54:1s–106s.Google Scholar
  119. 119.
    CGHFBC. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–27.CrossRefGoogle Scholar
  120. 120.
    WHO. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lancet. 1991;338:833–8.CrossRefGoogle Scholar
  121. 121.
    Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev. 2010;19:2496–502.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16:631–50.PubMedCrossRefGoogle Scholar
  123. 123.
    Wingo PA, Lee NC, Ory HW, Beral V, Peterson HB, Rhodes P. Age-specific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol. 1991;78:161–70.PubMedGoogle Scholar
  124. 124.
    Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc. 2006;81:1290–302.PubMedCrossRefGoogle Scholar
  125. 125.
    Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359:1085–92.PubMedCrossRefGoogle Scholar
  126. 126.
    Appleby P, Beral V, Berrington de Gonzalez A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609–21.PubMedCrossRefGoogle Scholar
  127. 127.
    Roura E, Travier N, Waterboer T, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC Cohort. PLoS One. 2016;11:e0147029.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Grimes DA. The safety of oral contraceptives: epidemiologic insights from the first 30 years. Am J Obstet Gynecol. 1992;166:1950–4.PubMedCrossRefGoogle Scholar
  129. 129.
    Bahamondes L, Valeria Bahamondes M, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update. 2015;21:640–51.PubMedCrossRefGoogle Scholar
  130. 130.
    CASH. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med. 1987;316:650–5.CrossRefGoogle Scholar
  131. 131.
    Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 2002;94:32–8.PubMedCrossRefGoogle Scholar
  132. 132.
    CASH. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA. 1987;257:796–800.CrossRefGoogle Scholar
  133. 133.
    CASH. Oral contraceptive use and the risk of endometrial cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA. 1983;249:1600–4.CrossRefGoogle Scholar
  134. 134.
    WHO. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 1991;49:186–90.CrossRefGoogle Scholar
  135. 135.
    Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med. 1996;41:419–27.PubMedGoogle Scholar
  136. 136.
    Leslie KK, Thiel KW, Yang S. Endometrial cancer: potential treatment and prevention with progestin-containing intrauterine devices. Obstet Gynecol. 2012;119:419–20.PubMedCrossRefGoogle Scholar
  137. 137.
    Brown AJ, Westin SN, Broaddus RR, Schmeler K. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol. 2012;119:423–6.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Gold MA, Coupey SM. Young women's attitudes toward injectable and implantable contraceptives. J Pediatr Adolesc Gynecol. 1998;11:17–24.PubMedCrossRefGoogle Scholar
  139. 139.
    Moore PJ, Adler NE, Kegeles SM. Adolescents and the contraceptive pill: the impact of beliefs on intentions and use. Obstet Gynecol. 1996;88:48s–56s.PubMedCrossRefGoogle Scholar
  140. 140.
    Rees HD, Bonsall RW, Michael RP. Pre-optic and hypothalamic neurons accumulate [3H]medroxyprogesterone acetate in male cynomolgus monkeys. Life Sci. 1986;39:1353–9.PubMedCrossRefGoogle Scholar
  141. 141.
    Reubinoff BE, Grubstein A, Meirow D, Berry E, Schenker JG, Brzezinski A. Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil Steril. 1995;63:516–21.PubMedCrossRefGoogle Scholar
  142. 142.
    Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception. 1997;55:131–7.PubMedCrossRefGoogle Scholar
  143. 143.
    Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. Contraception. 1998;58:345–9.PubMedCrossRefGoogle Scholar
  144. 144.
    Redmond G, Godwin AJ, Olson W, Lippman JS. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception. 1999;60:81–5.PubMedCrossRefGoogle Scholar
  145. 145.
    Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577–82.PubMedCrossRefGoogle Scholar
  146. 146.
    Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014 Jan 29;(1):CD003987.Google Scholar
  147. 147.
    Lopez LM, Edelman A, Chen-Mok M, Trussell J, Helmerhorst FM. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2011 Apr 13;(4):CD008815.Google Scholar
  148. 148.
    Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2013;88:503–8.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Schwallie PC, Assenzo JR. Contraceptive use--efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril. 1973;24:331–9.PubMedCrossRefGoogle Scholar
  150. 150.
    Polaneczky M, Guarnaccia M, Alon J, Wiley J. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Fam Plan Perspect. 1996;28:174–8.CrossRefGoogle Scholar
  151. 151.
    Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J Adolesc Health. 1999;24:433–6.PubMedCrossRefGoogle Scholar
  152. 152.
    Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med. 2006;160:40–5.PubMedCrossRefGoogle Scholar
  153. 153.
    Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011-2014. NCHS Data Brief. 2015 Nov;(219):1–8.Google Scholar
  154. 154.
    Chang T, Davis MM, Kusunoki Y, Ela EJ, Hall KS, Barber JS. Sexual behavior and contraceptive use among 18- to 19-year-old adolescent women by weight status: a longitudinal analysis. J Pediatr. 2015;167:586–92.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol. 2012;120:21–6.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203:547.e1–10.CrossRefGoogle Scholar
  157. 157.
    Fotherby K, Koetsawang S. Metabolism of injectable formulations of contraceptive steroids in obese and thin women. Contraception. 1982;26:51–8.PubMedCrossRefGoogle Scholar
  158. 158.
    Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2002;15:79–82.PubMedCrossRefGoogle Scholar
  159. 159.
    Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. Obstet Gynecol. 2011;117:793–7.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol. 2011;117:33–40.PubMedCrossRefGoogle Scholar
  161. 161.
    Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002;77:S13–8.PubMedCrossRefGoogle Scholar
  162. 162.
    Dragoman MV, Simmons KB, Paulen ME, Curtis KM. Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review. Contraception. 2017;95:117–29.PubMedCrossRefGoogle Scholar
  163. 163.
    Lopez LM, Bernholc A, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. The Cochrane database of systematic reviews. 2016:Cd008452.Google Scholar
  164. 164.
    Shaw KA, Edelman AB. Obesity and oral contraceptives: a clinician's guide. Best Pract Res Clin Endocrinol Metab. 2013;27:55–65.PubMedCrossRefGoogle Scholar
  165. 165.
    Edelman AB, Carlson NE, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception. 2009;80:119–27.PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Higginbotham S. Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091. Contraception. 2009;80:583–90.PubMedCrossRefGoogle Scholar
  167. 167.
    ACOG. Committee Opinion No 544: Over-the-counter access to oral contraceptives. Obstet Gynecol. 2012;120:1527–31.CrossRefGoogle Scholar
  168. 168.
    Tepper NK, Curtis KM, Steenland MW, Marchbanks PA. Physical examination prior to initiating hormonal contraception: a systematic review. Contraception. 2013;87:650–4.PubMedCrossRefGoogle Scholar
  169. 169.
    Tepper NK, Steenland MW, Marchbanks PA, Curtis KM. Laboratory screening prior to initiating contraception: a systematic review. Contraception. 2013;87:645–9.PubMedCrossRefGoogle Scholar
  170. 170.
    Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ. 2010;340:c927.PubMedPubMedCentralCrossRefGoogle Scholar
  171. 171.
    Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501.PubMedCrossRefGoogle Scholar
  172. 172.
    Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod. 2006;21:2304–11.PubMedCrossRefGoogle Scholar
  173. 173.
    Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. The Cochrane database of systematic reviews. 2006:Cd003855.Google Scholar
  174. 174.
    Larsson G, Milsom I, Lindstedt G, Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception. 1992;46:327–34.PubMedCrossRefGoogle Scholar
  175. 175.
    Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception. 1990;42:497–506.PubMedCrossRefGoogle Scholar
  176. 176.
    Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med. 2001;345:266–75.PubMedCrossRefGoogle Scholar
  177. 177.
    Goodman NF, Bledsoe MB, Cobin RH, et al. American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders. Endocr Pract. 2001;7:120–34.PubMedCrossRefGoogle Scholar
  178. 178.
    Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1105–20.PubMedCrossRefGoogle Scholar
  179. 179.
    Klove KL, Roy S, Lobo RA. The effect of different contraceptive treatments on the serum concentration of dehydroepiandrosterone sulfate. Contraception. 1984;29:319–24.PubMedCrossRefGoogle Scholar
  180. 180.
    Vujovic S, Brincat M, Erel T, et al. EMAS position statement: managing women with premature ovarian failure. Maturitas. 2010;67:91–3.PubMedCrossRefGoogle Scholar
  181. 181.
    Torrealday S, Pal L. Premature Menopause. Endocrinol Metab Clin N Am. 2015;44:543–57.CrossRefGoogle Scholar
  182. 182.
    Kodaman PH. Early menopause: primary ovarian insufficiency and surgical menopause. Semin Reprod Med. 2010;28:360–9.PubMedCrossRefGoogle Scholar
  183. 183.
    ACOG. Committee Opinion No 699: adolescent pregnancy, contraception, and sexual activity. Obstet Gynecol. 2017;129:e142–e9.CrossRefGoogle Scholar
  184. 184.
    Diedrich JT, Klein DA, Peipert JF. Long-acting reversible contraception in adolescents: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216:364.e1–e12.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Section of Reproductive Endocrinology and Infertility, Department of Obstetrics and GynecologyThe University of ChicagoChicagoUSA
  2. 2.Section of Family Planning and Contraceptive Research, Department of Obstetrics and GynecologyThe University of ChicagoChicagoUSA

Personalised recommendations